Chris Broderick brings over 15 years of biotechnology industry experience to his role as Founder, President and Chief Executive Officer of Merakris Therapeutics. Since founding Merakris in 2016, Mr. Broderick has leveraged his deep expertise across business development, sales management, product launches, quality and regulatory affairs, and market access to lead the company’s pioneering investigational drug development program. This program received FDA clearance in 2021.
Prior to launching Merakris, Mr. Broderick held various leadership positions in the human tissue technologies sector before expanding into regulatory and biopharmaceutical manufacturing. He holds a Bachelor of Business Administration from Appalachian State University and is currently a Master of Science in biomanufacturing candidate from North Carolina State University with a research focus in bioprocess optimization of cell-free therapeutics.
A co-author on several peer-reviewed publications in leading journals, Mr. Broderick completed additional regulatory affairs training at Duke University. His vision and leadership have been instrumental in building Merakris into an emerging leader in novel therapeutics development.